Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD
Klaus F. Rabe,Fernando J. Martinez,Gary T. Ferguson,Chen Wang,Dave Singh,Jadwiga A. Wedzicha,Roopa Trivedi,Earl St Rose,Shaila Ballal,J. McLaren,Patrick Darken,Magnus Aurivillius,Colin Reisner,Paul Dorinsky +13 more
Reads0
Chats0
TLDR
Triple therapy with twice-daily budesonide resulted in a lower rate of moderate or severe COPD exacerbations than glycopyrrolate-formoterol or budesonid- formoterol.Abstract:
Background Triple fixed-dose regimens of an inhaled glucocorticoid, a long-acting muscarinic antagonist (LAMA), and a long-acting β2-agonist (LABA) for chronic obstructive pulmonary diseasread more
Citations
More filters
Journal ArticleDOI
Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study.
Fernando J. Martinez,Klaus F. Rabe,Gary T. Ferguson,Jadwiga A. Wedzicha,Dave Singh,Chen Wang,Kimberly Rossman,Earl St Rose,Roopa Trivedi,Shaila Ballal,Patrick Darken,Magnus Aurivillius,Colin Reisner,Paul Dorinsky +13 more
TL;DR: To assess the robustness of the ETHOS mortality findings after additional data retrieval for patients missing Week 52 vital status in the original analyses, triple therapy with BGF 320 was not shown to significantly reduce the risk of death compared with BFF, in patients with COPD.
Journal ArticleDOI
Chronic obstructive pulmonary disease
TL;DR: In this article , the authors present an overview of recent advances in epidemiology, pathophysiology, imaging, diagnosis, and treatment of chronic obstructive pulmonary disease (COPD).
Journal ArticleDOI
Spanish COPD Guidelines (GesEPOC) 2021: Updated Pharmacological treatment of stable COPD
Jiemin Zhu,Marc Miravitlles,Myriam Calle,Jesús Molina,Pere Almagro,José-Tomás Gómez,Juan Antonio Trigueros,Borja G. Cosío,Ciro Casanova,José Luis López-Campos,Juan Antonio Riesco,Pere Simonet,David Rigau,Joan B. Soriano,Julio Ancochea,Juan José Soler-Cataluña +15 more
TL;DR: The Spanish COPD Guidelines (GesEPOC) were first published in 2012, and since then have undergone a series of updates incorporating new evidence on the diagnosis and treatment of COPD as discussed by the authors.
Journal ArticleDOI
Towards the elimination of chronic obstructive pulmonary disease: a Lancet Commission
TL;DR: Despite substantial progress in reducing the global impact of many non-communicable diseases, including heart disease and cancer, morbidity and mortality due to chronic respiratory disease continues to increase despite the identification of cigarette smoking as the major risk factor for the disease more than 50 years ago as discussed by the authors .
Journal ArticleDOI
Actualización 2021 de la Guía Española de la EPOC (GesEPOC). Tratamiento farmacológico de la EPOC estable
TL;DR: The Spanish COPD Guidelines (GesEPOC) were first published in 2012, and since then have undergone a series of updates incorporating new evidence on the diagnosis and treatment of COPD as mentioned in this paper .
References
More filters
Journal ArticleDOI
Standardisation of spirometry
Martin R. Miller,John L. Hankinson,Vito Brusasco,Felip Burgos,Richard Casaburi,Allan L. Coates,Robert O. Crapo,Paul L. Enright,C.P.M. van der Grinten,P. Gustafsson,R. Jensen,D.C. Johnson,Neil R. MacIntyre,Roy T. McKay,Daniel Navajas,O. F. Pedersen,Riccardo Pellegrino,Giovanni Viegi,J. Wanger +18 more
TL;DR: This research presents a novel and scalable approach called “Standardation of LUNG FUNCTION TESTing” that combines “situational awareness” and “machine learning” to solve the challenge of integrating nanofiltration into the energy system.
Journal ArticleDOI
A sharper Bonferroni procedure for multiple tests of significance
TL;DR: In this article, a simple procedure for multiple tests of significance based on individual p-values is derived, which is sharper than Holm's (1979) sequentially rejective procedure.
Journal ArticleDOI
Global initiative for chronic obstructive lung disease.
Lynn B. Gerald,William C. Bailey +1 more
TL;DR: Representatives from many countries serve as a network for the dissemination and implementation of programs for diagnosis, management, and prevention of COPD.
Journal ArticleDOI
Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.
Julie A. Anderson,Bartolome R. Celli,Gary T. Ferguson,Christine Jenkins,Paul W. Jones,Julie C. Yates,Jørgen Vestbo +6 more
TL;DR: The reduction in death from all causes among patients with COPD in the combination-therapy group did not reach the predetermined level of statistical significance, and there were significant benefits in all other outcomes among these patients.
Journal ArticleDOI
Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD
David A. Lipson,Frank Barnhart,Noushin Brealey,Jean Brooks,Gerard J. Criner,Nicola C. Day,Mark T. Dransfield,David M.G. Halpin,MeiLan K. Han,C. Elaine Jones,Sally Kilbride,Peter Lange,David A. Lomas,Fernando J. Martinez,Dave Singh,Maggie Tabberer,Robert A. Wise,Steven Pascoe +17 more
TL;DR: Triple therapy with fluticasone furoate, umeclidinium, and vilanterol resulted in a lower rate of moderate or severe COPD exacerbations than flutic asonefuroate–vilanterol or u meclid inium–vilAnterol in this population.